BATTLING BREAST CANCER

摘要: MOST DOCTORS AREN'T ACCUSTOMED TO BEING GREETed like the Rolling Stones playing Madison Square Garden. But in spring 2005, at annual meeting of American Society Clinical Oncologists (ASCO), clinicians reporting results from a trial Genentech's breast cancer drug Herceptin got taste rock star treatment. A packed auditorium oncologists broke out applause upon hearing that adding monoclonal antibody to patient's chemotherapy regimen after surgery nearfy halved risk disease ever coming back In field incremental progress—new drugs often extend life by just months rather than years—the news was considered major breakthrough. Herceptin's success is based on its highly selective nature: The binds HER2 receptor, growth factor protein overexpressed roughly 25% patients. First approved U.S. 1998 treat most advanced cases HER2-positive ...